亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會(huì)員登錄|免費(fèi)注冊(cè)|忘記密碼|管理入口 返回主站||保存桌面|手機(jī)瀏覽|聯(lián)系方式|購物車
企業(yè)會(huì)員第1年

Hubei YuanCheng Pharmaceutical Co., Ltd.  

醫(yī)藥原料 香精香料 激素甾體

搜索
新聞中心
產(chǎn)品分類
聯(lián)系方式
  • 聯(lián)系人:陳杏
  • 電話:027-68886685
  • 郵件:chenx1150@live.cn
  • 傳真:027-88048077
  • QQ:2355327129
站內(nèi)搜索
 
榮譽(yù)資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應(yīng)產(chǎn)品 > 三磷酸腺苷二鈉(ATP)
三磷酸腺苷二鈉(ATP)
單價(jià) 面議對(duì)比
詢價(jià) 暫無
發(fā)貨 湖北武漢市付款后3天內(nèi)
品牌 南箭
型號(hào) 三磷酸腺苷二鈉(ATP)
規(guī)格 99%
過期 長(zhǎng)期有效
更新 2014-03-05 11:49
 
詳細(xì)信息


 三磷酸腺苷二鈉(ATP)


產(chǎn)品類別: 醫(yī)藥原料和中間體
產(chǎn)品含量: 98%
化學(xué)式: C9H12N2O4
CAS編號(hào): 2964-48-9
質(zhì)量標(biāo)準(zhǔn): CP2005
包裝規(guī)格: 25KG/桶
產(chǎn)品說明: 白色粉未
分子式   C10H16N5O13P3

分子量   507.184

用作:藥物中間體 

藥理作用:三磷酸腺苷二鈉是核苷酸衍生物,參與體內(nèi)脂肪、蛋白質(zhì)、糖、核酸以及核苷酸

©2025 Hubei YuanCheng Pharmaceutical Co., Ltd. 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問量:10030  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |